Abstracts tagged "human leukocyte antigens (HLA) and juvenile idiopathic arthritis (JIA)"

Abstract Number: 1474 • 2015 ACR/ARHP Annual Meeting
8-Year Follow-up Study: Differences Between HLA-B27 Positive and Negative Children with Juvenile Idiopathic Arthritis in Finland
Suvi Peltoniemi¹, Ellen Berit Nordal^2,3, Pekka Lahdenne⁴ and Kristiina Aalto⁴, ¹Department of Pediatric Rheumatology, Children's Hospital, Helsinki University Hospital, Helsinki, Finland, ²Department of Pediatrics, University Hospital of North Norway, Tromsø, Norway, ³Department of Clinical Medicine, UIT The Arctic University of Norway, Tromsø, Norway, ⁴Department of Pediatrics, Children's Hospital, Helsinki University Hospital, Helsinki, Finland
Background/Purpose: Long-term studies have shown that many patients with juvenile idiopathic arthritis (JIA) still suffer from persistent inflammation and disability as adults. Because of the…
Abstract Number: 318 • 2014 ACR/ARHP Annual Meeting
HLA-B27 Subtypes in Enthesitis Related Arthritis Category of Juvenile Idiopathic Arthritis
Rajni Srivastava¹, Shikha Agnihotry², Rakesh Aggarwal³ and Amita Aggarwal¹, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Bioinformatics, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: HLA-B27 has a high degree of genetic polymorphism, with more than 105 known subtypes. Enthesitis Related Arthritis (ERA) is most common form of Juvenile Idiopathic Arthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].